Exhibit 10.1

    

    
       

        

      Execution Copy

    

    

    

    
      AMENDMENT TO EMPLOYMENT AGREEMENT

      

      

      This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made as of this 14th day of November 2018 (the “Effective Date”), by and between
          Douglas J. Swirsky (the “Executive”) and Rexahn Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and amends the EMPLOYMENT AGREEMENT dated January 2, 2018 (the “Employment Agreement”), by and between the Executive and the Company.

      

      

      RECITALS

      

      

      WHEREAS, effective as of the Effective Date, the Board of Directors of the Company has promoted the Executive to the office of Chief
          Executive Officer of the Company.

      

      

      WHEREAS, as a result of this promotion, the Company and the Executive wish to amend the Employment Agreement on the term and subject
          to the conditions set forth in this Amendment to address certain modifications to the terms of the Executive’s employment.

      

      

      NOW, THEREFORE, in consideration of the foregoing, and the mutual covenants and agreements set forth herein, the parties hereto agree
          as follows:

      

      

      1.            Defined Terms.  Capitalized terms used in this Amendment without definition shall have the meanings given those terms in the Employment Agreement.

       

      

      2.            Amendment to Section 2 (Title).  Section 2 of the Employment Agreement is deleted in its entirety and in its place the following sentence shall be inserted:

      

      

      “The Executive will serve as the President and Chief Executive Officer (the “CEO”) of the Company.”

      

      

      3.            Amendment to Section 3 (Duties).  The first sentence of Section 3 of the Employment Agreement is deleted and in its place the following sentence shall be inserted:

      

      

      “The Executive is responsible for duties commensurate with his position as the President and CEO of the Company and such other duties
          as may be assigned to him from time to time by the Company’s Board of Directors (the “Board”).

      

      

      4.            Amendment to Section 4 (Reporting).  Section 4 of the Employment Agreement is deleted in its entirety and in its place the following sentence shall be inserted:

        

      

      “The Executive will report directly to the Board.”

      

      

      
        1

        
          


      

      
        Execution Copy

      

       

        

      5.           Amendment to Section 6 (Compensation).  Commencing on the Effective Date, the Executive’s Base Salary shall be increased to Four Hundred and Twenty-Five Thousand Dollars ($425,000.00).  For calendar
          year 2019 and each year thereafter, the Executive’s Target Bonus percentage shall be increased from forty percent (40%) to fifty percent (50%).  For clarity, the Executive’s Target Bonus percentage for calendar year 2018 shall remain forty
          percent (40%).

       

      

      6.            Additional Stock Option Award.

      

      

      a.          On the Effective Date, the Company shall grant the
          Executive an option to purchase up to Five Hundred Thousand (500,000) shares of the Company’s common stock (the “CEO Option Grant”).  The
          CEO Option Grant shall vest as follows: twenty-five percent (25%) of the shares subject to the CEO Option Grant shall vest on the first anniversary of the Effective Date; and thereafter one forty-eighth (1/48th) of the shares subject
          to the CEO Option Grant shall vest in monthly installments on the first business day of each month (beginning on the first business day of December 2019), until the CEO Option Grant is fully vested.  The CEO Option Grant shall be subject to such
          other terms and conditions as are set forth in the Stock Option Agreement and the Company’s Stock Option Plan.

       

      

      b.          The CEO Option Grant shall be included within the
          provisions of Sections 8(b)(vii) and 8(b)(viii) of the Employment Agreement.

      

      

      7.            Amendments to Section 7 (Termination of Employment).  Section 7(c)(iv) of the Employment Agreement is deleted in its entirety and in its place the following clause shall be inserted:

      

      

      “the Executive’s material failure, neglect or refusal to perform his duties under this Agreement, or to follow the lawful written
          directions of the Board;”

      

      

      8.            No Other Amendments; Employment Agreement still in Effect.  Except as specifically set forth in this Amendment, or as the context of this Amendment may require, the terms and conditions of the
          Employment Agreement shall remain in full force and effect.

      

      

      remainder of page intentionally left blank

      signatures follow

      

      

      
        2

        
          


      

      Execution Copy

      

      

      IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

      

      

      	
              on behalf of

            	 	 
	
              REXAHN PHARMACEUTICALS, INC.

            	
              EXECUTIVE

            	 
	 	 	 
	
              By:

            	
              /s/ Peter Brandt

            	 	
              /s/ Douglas J. Swirsky

            	 


      	
              Name:

            	
              Peter Brandt

            	
              Name: Douglas J. Swirsky

            
	
              Title:

            	
              Chairman of the Board of Directors

            	 


      

      

      

      

      3